Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Carbatrol price, strengths & recalls

Brand of carbamazepine (generic)

Pharmacies pay $50.83 for 30 capsules of Carbatrol 200 mg (12 hr) extended-release capsule this week, and from $50.83 to $50.97 across its 3 priced strengths and forms. The generic, carbamazepine, costs pharmacies from $3.58. It is in shortage (being discontinued). It has 14 recalls on record, none ongoing. Its official label last changed on August 25, 2026.

Being discontinuedBrand
Pharmacies pay$50.83for 30 capsules of 200 mg (12 hr) extended-release capsule+0.1% in 4 weeks
Fair cash price
$68.95
Strengths
3
Makers
1
Updated
Nov 11

Carbatrol price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
100 mg (12 hr) extended-release capsule Brand$1.70$50.97 / 30 capsulesNo change-0.5%
200 mg (12 hr) extended-release capsule Brand$1.69$50.83 / 30 capsules+0.1%+0.2%
300 mg (12 hr) extended-release capsule Brand$1.70$50.86 / 30 capsulesNo change-0.3%

The lowest cost per capsule is 200 mg (12 hr) extended-release capsule at $1.69. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Carbatrol vs generic carbamazepine

Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:

StrengthBrandGenericBrand costs
100 mg (12 hr) extended-release capsule$50.97$32.801.6x
200 mg (12 hr) extended-release capsule$50.83$30.981.6x
300 mg (12 hr) extended-release capsule$50.86$33.951.5x
GenericCarbamazepine prices

Supply status: shortages & recalls

In shortage3 products are short or being discontinued
3 ongoing recalls14 recalls on record

Shortages

  • Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug
  • Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug
  • Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 14 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for carbatrol? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 25, 2026
Version41 of 20
EffectiveAug 17, 2026
Read the label

CARBATROL®(carbamazepine) Extended-Release Capsules100 mg, 200 mg and 300 mgRx only

This drug has a boxed warning

WARNING

SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE

SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBATROL®. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBATROL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS).

APLASTIC ANEMIA AND AGRANULOCYTOSIS

APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE. DATA FROM A POPULATION-BASED CASE-CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.

ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED PLATELET OR WHITE BLOOD CELL COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE, DATA ARE NOT AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE OR OUTCOME. HOWEVER, THE VAST MAJORITY OF THE CASES OF LEUKOPENIA HAVE NOT PROGRESSED TO THE MORE SERIOUS CONDITIONS OF APLASTIC ANEMIA OR AGRANULOCYTOSIS.

BECAUSE OF THE VERY LOW INCIDENCE OF AGRANULOCYTOSIS AND APLASTIC ANEMIA, THE VAST MAJORITY OF MINOR HEMATOLOGIC CHANGES OBSERVED IN MONITORING OF PATIENTS ON CARBAMAZEPINE ARE UNLIKELY TO SIGNAL THE OCCURRENCE OF EITHER ABNORMALITY. NONETHELESS, COMPLETE PRETREATMENT HEMATOLOGICAL TESTING SHOULD BE OBTAINED AS A BASELINE. IF A PATIENT IN THE COURSE OF TREATMENT EXHIBITS LOW OR DECREASED WHITE BLOOD CELL OR PLATELET COUNTS, THE PATIENT SHOULD BE MONITORED CLOSELY. DISCONTINUATION OF THE DRUG SHOULD BE CONSIDERED IF ANY EVIDENCE OF SIGNIFICANT BONE MARROW DEPRESSION DEVELOPS.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA020712 · Takeda Pharms USA
First approved
September 30, 1997 (29 years ago)
Latest approved change
April 11, 2023
Approved label
PDF, Apr 12, 2023
Generic makers
26 approved generic applications on the market

Carbatrol questions

How much does carbatrol cost without insurance?

Pharmacies pay about $50.83 for 30 capsules of carbatrol 200 mg (12 hr) extended-release capsule ($1.69 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $68.95. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Carbatrol?

Yes: carbamazepine. Pharmacies pay from $3.58 for it. Compare carbamazepine prices.

Is carbatrol in shortage?

Yes. 3 products are listed as in shortage or being discontinued (being discontinued). See which ones.

Has carbatrol been recalled?

14 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the carbatrol label last change?

The official label was last updated on August 25, 2026 (version 41). See what changed.

Talk about carbatrol

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.